Research programme: erythrocyte encapsulated tumour antigen immunotherapies - ERYtech

Drug Profile

Research programme: erythrocyte encapsulated tumour antigen immunotherapies - ERYtech

Alternative Names: ERYMMUNE; Tumour vaccines - ERYtech

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator ERYtech Pharma
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Mar 2017 Preclinical trials in Cancer in France (Parenteral) before March 2017
  • 07 Mar 2017 Pharmacodynamics data from a preclinical trial in Cancer released by ERYTECH Pharma
  • 12 Sep 2016 Early research in Cancer in France (Parenteral) (ERYtech pipeline, September 2016) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top